Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of JPB898 (proposed Nivolumab Biosimilar) and US-licensed and EU-authorized Opdivo in Combination with Yervoy in Participants with Untreated Advanced (unresectable/metastatic) Melanoma

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of JPB898 (proposed Nivolumab Biosimilar) and US-licensed and EU-authorized Opdivo in Combination with Yervoy in Participants with Untreated Advanced (unresectable/metastatic) Melanoma

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Ipilimumab; Nivolumab
  • Indications Malignant melanoma
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Sandoz

    • Most Recent Events

    • 26 Sep 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top